Close Menu

Omeros, a Seattle-based drug discovery firm, is getting an injection of money from Washington State's Life Sciences Discovery Fund and local entrepreneur and billionaire Paul Allen, Xconomy reports. Omeros is trying to come up with therapeutics that bind G-protein coupled receptors — targets that have been deemed "undruggable" by many.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.